- Home
- FDMT vs PHAT Comparison
FDMT vs PHAT Comparison
Compare FDMT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | PHAT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 759.7M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FDMT | PHAT |
|---|---|---|
| Price | $14.19 | $8.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $31.71 | $19.83 |
| AVG Volume (30 Days) | ★ 1.0M | 1.0M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.79 | ★ 42.72 |
| EPS | N/A | ★ N/A |
| Revenue | $85,209,000.00 | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | $70.28 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 230194.60 | 216.93 |
| 52 Week Low | $6.47 | $8.21 |
| 52 Week High | $16.93 | $18.31 |
Technical Indicators
Market Signals| Indicator | FDMT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 42.22 |
| Support Level | $13.67 | $8.46 |
| Resistance Level | $16.93 | $9.75 |
| Average True Range (ATR) | 0.95 | 0.51 |
| MACD | -0.19 | 0.07 |
| Stochastic Oscillator | 15.87 | 26.32 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.